

SUPPLEMENTARY TABLES

Supplementary Table 3. The potential SIAH1-interacting proteins.

| Gene Name | Unique peptides | Sequence coverage [%] |
|-----------|-----------------|-----------------------|
| RPS3 | 25 | 75.7 |
| HNRNPA2B1 | 27 | 76.8 |
| RPL7 | 23 | 70.2 |
| HIST2H2AB | 2 | 70 |
| NME2 | 6 | 75 |
| PFN1 | 13 | 78.6 |
| NPM1 | 24 | 75.5 |
| ENO1 | 27 | 71.2 |
| RPLP2 | 8 | 80 |
| NEDD8 | 7 | 81.5 |
| HIST3H2BB | 2 | 76.2 |
| PRDX1 | 12 | 79.9 |
| RPL24 | 22 | 73.2 |
| UBA52 | 2 | 71.1 |
| RPS27A | 7 | 73.1 |
| PPIA | 17 | 85.5 |
| HIST1H4A | 16 | 72.8 |
| UBE2N | 12 | 70.4 |
| VIM | 36 | 72.3 |
| PRDX6 | 17 | 72.3 |

Supplementary Table 4. The potential ubiquitination sites.

| Gene Name | Positions within proteins | Score | GlyGly (K) Probabilities | OE/NC | P value (Significance A) |
|-----------|---------------------------|--------|--------------------------------|----------|--------------------------|
| RPS3 | 214 | 176.53 | KPLPDHVSVIPEPK(1)DEILPTTPISEQK | 3.21965 | 0.00983847 |
| RPS3 | 10 | 106.68 | K(1)FVADGIFK | 0.33357 | 0.0373192 |
| RPS3 | 8 | 91.626 | AVQISK(1)K(1)R | 0.315526 | 0.0281246 |
| RPS3 | 141 | 146.79 | GCEVVVSGK(1)LR | 0.284557 | 0.0161287 |
| RPS3 | 230 | 133.32 | GGK(1)PEPPAMPQPVPTA | 0.916819 | 0.981948 |
| RPS3 | 202 | 63.894 | K(1)PLPDHVSVIPEPK | 0.642557 | 0.45523 |
| RPS3 | 90 | 70.96 | FGFP EG SVEL YAEK(1)VATR | 0.593273 | 0.363198 |
| RPS3 | 62 | 147.2 | TQNV LGEK(1)GRR | 0.495039 | 0.201236 |
| RPS3 | 197 | 100.55 | IMLPWDPTGK(0.992)IGPK(0.008) | 0.432506 | 0.120391 |
| RPS3 | 75 | 222.08 | I R E L T A V V Q K(1)R | 0.385161 | 0.0735663 |
| RPS3 | 7 | 97.068 | AVQISK(1)K(1)R | 0.359152 | 0.0533932 |

Supplementary Table 5. Clinical and pathological features of EOC patients.

| Characteristics | Age (years) | Pathological type | FIGO stage | Grade | Progression-free survival (months) |
|-----------------|----------------|---------------------------|------------|----------|---------------------------------------|
| EOC1 | 66 | serous mucinous carcinoma | IIIA1(i) | Low | >6 |
| EOC2 | 62 | serous carcinoma | IIIA2 | Moderate | >6 |
| EOC3 | 70 | mucinous carcinoma | IVA | High | >6 |
| EOC4 | 65 | serous carcinoma | IIIC | High | >6 |
| EOC5 | 63 | serous mucinous carcinoma | IIIC | Moderate | >6 |
| EOC6 | 64 | serous carcinoma | IVA | Moderate | >6 |
| EOC7 | 68 | serous carcinoma | IIIC | High | >6 |
| EOC8 | 67 | clear cell carcinoma | IVA | High | >6 |
| EOC9 | 69 | endometrioid carcinoma | IIIA1(ii) | Low | >6 |
| EOC10 | 71 | mucinous carcinoma | IIIC | Moderate | >6 |
| EOC11 | 65 | serous carcinoma | IVA | Low | >6 |
| EOC12 | 59 | serous carcinoma | IVA | High | >6 |
| EOC13 | 60 | serous carcinoma | IIIC | High | <6 |
| EOC14 | 68 | serous mucinous carcinoma | IIIC | Low | <6 |
| EOC15 | 68 | mucinous carcinoma | IVA | High | <6 |
| EOC16 | 65 | clear cell carcinoma | IIIC | High | <6 |
| EOC17 | 66 | serous carcinoma | IIIB | Moderate | <6 |
| EOC18 | 69 | serous carcinoma | IIIA2 | Moderate | <6 |
| EOC19 | 72 | serous carcinoma | IIIC | High | <6 |
| EOC20 | 66 | serous carcinoma | IIIB | High | <6 |
| EOC21 | 70 | serous carcinoma | IVB | High | <6 |
| EOC22 | 65 | serous carcinoma | IIIC | Moderate | <6 |
| EOC23 | 76 | serous carcinoma | IIIC | High | <6 |
| EOC24 | 60 | serous carcinoma | IVA | High | <6 |